Introduction: Who Should Undergo Diagnostics and When

If you notice certain changes in your body, it may be time to see a healthcare provider for diagnostic testing. Blood on or in your stool is one of the most important warning signs that should never be ignored. This might appear as bright red blood in the toilet, dark-colored stool, or blood visible after wiping. While blood in stool doesn’t always mean cancer—it can come from other conditions like hemorrhoids—it’s always better to get checked out by a doctor^[3].

Persistent changes in how you use the bathroom are another reason to seek diagnostic testing. If you experience ongoing constipation or diarrhea that doesn’t go away, or if you feel like you still need to poop even after going to the bathroom, these could be signs worth investigating. Belly pain without a clear cause, especially if it’s severe or doesn’t improve, should also prompt a visit to your healthcare provider^[3].

Other symptoms that warrant diagnostic evaluation include a bloated stomach that lasts more than a week or keeps getting worse. Many things can cause bloating, but when it persists, it deserves medical attention^[3].

Regular screening is particularly important even if you don’t have symptoms. Colon cancer typically affects people age 50 and older, though the number of younger people aged 20 to 49 developing this cancer has been increasing by about 1.5% each year. Healthcare providers recommend that people start regular screening at age 45 to catch problems early^[3].

Classic Diagnostic Methods Used to Identify Stage II Colon Cancer

The process of diagnosing colon cancer and determining its stage involves several types of tests and procedures. These work together to give doctors a complete picture of what’s happening in your body.

Colonoscopy and Visual Examination

Colonoscopy is one of the most important diagnostic tools for detecting colon cancer. During this procedure, a healthcare professional inserts a long, flexible tube called a colonoscope into your rectum. This tube has a tiny video camera attached to its end, which allows the doctor to view the entire length of your colon and rectum on a monitor. The colonoscope can do more than just look—doctors can pass surgical tools through the tube to take tissue samples or remove growths called polyps during the same procedure^[19].

What makes colonoscopy particularly valuable is its dual role as both a screening and diagnostic tool. If your doctor sees something suspicious during a routine screening colonoscopy, they can immediately take action by collecting samples for further testing^[19].

Biopsy and Laboratory Analysis

A biopsy involves removing a small sample of tissue so it can be examined in a laboratory. For colon cancer, doctors often collect the tissue sample during a colonoscopy. Sometimes surgery is necessary to obtain the tissue sample. Once the sample reaches the lab, specialists perform tests to determine whether the cells are cancerous and how quickly they’re growing^[19].

Laboratory tests on the biopsy sample provide crucial information beyond just confirming cancer. They reveal specific characteristics of the cancer cells that help your healthcare team understand your prognosis, which is the likely course and outcome of your disease. These test results also guide decisions about what treatments will work best for your specific situation^[19].

Blood Tests

While blood tests alone cannot diagnose colon cancer, they provide valuable supporting information. These tests help doctors understand your overall health, including how well your kidneys and liver are functioning. A blood test might reveal a low level of red blood cells, which could indicate that a colon cancer is causing bleeding somewhere in your digestive system^[19].

Some colon cancers produce a protein called carcinoembryonic antigen, or CEA. Doctors can track the level of CEA in your blood over time. These measurements help show whether cancer is responding to treatment. After treatment ends, CEA blood tests can help detect if the cancer has returned^[19].

Imaging Tests and Staging

Once cancer is confirmed, doctors need to determine its stage—that is, how far it has spread. Stage II colon cancer means the cancer has grown into the outer layers of the colon or rectum but hasn’t spread to lymph nodes or other organs. To make this determination, doctors use various imaging techniques and surgical examination^[1].

Stage IIA means cancer has spread into a layer of the colon called the muscularis propria but hasn’t grown beyond it. It hasn’t reached any organs or lymph nodes. Stage IIB indicates that cancer has spread through to the outermost layer of the colon wall, called the serosa, but still hasn’t reached other organs or lymph nodes. Stage IIC means cancer has grown through the entire colon wall and into nearby tissue, though it still hasn’t spread to organs or lymph nodes^[1][6].

Lymph Node Examination

An essential part of diagnosing stage II colon cancer involves examining lymph nodes removed during surgery. Healthcare providers look for cancer cells in these small, bean-shaped structures that are part of your immune system. In stage II disease, no cancer cells are found in the lymph nodes—this is indicated by the designation “N0” in medical reports^[7].

The number of lymph nodes examined matters greatly. Doctors prefer to examine at least 12 lymph nodes to be confident in the staging. When fewer than 12 lymph nodes are removed or assessed, it’s considered a high-risk feature because there’s less certainty that cancer hasn’t spread to lymph nodes that weren’t examined^[11][12].

Diagnostics for Clinical Trial Qualification

When patients with stage II colon cancer consider participating in clinical trials, certain diagnostic tests and assessments become standard requirements for enrollment. Clinical trials test new treatments or compare different treatment approaches, so researchers need specific information about each patient’s condition to ensure they’re good candidates for the study.

Risk Stratification Tests

Clinical trials often require detailed information about risk factors that help predict whether cancer is likely to return. Doctors classify stage II colon cancer into low-risk, intermediate-risk, and high-risk categories based on specific features of the tumor. These clinico-pathological features—characteristics related to both clinical observations and laboratory findings—help researchers determine which patients might benefit most from a particular treatment being studied^[4].

Several features indicate higher risk. If the tumor is classified as T4, meaning it extends through the colon wall and attaches to or invades nearby structures or organs, this places a patient in a higher-risk category. Other high-risk features include finding cancer in blood vessels or in the space surrounding nerves (called lymphovascular invasion and perineural invasion), tumors that are poorly formed or high-grade, blockage in the intestine, or a tear or hole in the intestine^[11][12].

Molecular and Genetic Testing

Modern clinical trials increasingly require molecular testing of the tumor tissue. One particularly important test looks for microsatellite instability, abbreviated as MSI. Microsatellites are short, repeated sequences of DNA, and when they’re unstable, it indicates problems with the body’s ability to repair DNA damage. Tumors with microsatellite instability behave differently from those without it^[4].

Patients with stage II colon cancer that shows microsatellite instability, particularly those with T3 tumors (meaning the cancer invaded through the outer layer of the colon into surrounding tissue), tend to have excellent outcomes. Research has shown that these patients may not require chemotherapy after surgery. This molecular information helps clinical trial researchers identify which patients might benefit from specific treatments and which ones might safely avoid certain therapies^[4][7].

Another type of testing looks at gene expression patterns in the tumor. A validated recurrence score based on these patterns provides more detailed prognostic information than traditional features alone. This score helps predict the likelihood that cancer will come back after treatment. For patients with microsatellite-stable disease (tumors without microsatellite instability), this recurrence score can be particularly valuable in discussions about whether to pursue additional treatment after surgery^[7].

Baseline Health Assessments

Before enrolling in a clinical trial, patients undergo comprehensive health assessments to ensure they can safely participate. These assessments evaluate the patient’s overall condition and any other health problems they might have, called comorbidities. These evaluations help researchers determine if a patient is healthy enough for the treatments being studied and establish baseline measurements for comparison as the trial progresses^[4].

In Western countries, screening for dihydropyrimidine dehydrogenase deficiency is mandatory before starting certain chemotherapy drugs called fluoropyrimidines, which are common treatments for colon cancer. This enzyme helps break down these drugs in the body. People with deficiency of this enzyme can experience severe, even life-threatening side effects from fluoropyrimidine chemotherapy^[4].